Choi, Y., Shewale, S., Lin, D., McAndrew, P., El-Masry, M., Banerjee, N., Chung, C. T., Hoffman, D. M. J., Britten, K., Bitar, J. S., LeVee, A. A., Corgiat, B., Davis, J., Mueller, C., Yuan, Y. (2026). Proteomics-based phosphorylated AKT S473 and PI3K/AKT inhibitors in patients with hormone receptor–positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e13053